PegBio
PegBio Co., Ltd. (派格生物) is a China-based, Hong Kong-listed clinical-stage biopharmaceutical company developing GLP-1 receptor agonist-based therapeutics across a six-asset pipeline targeting type 2 diabetes, obesity, MASH, opioid-induced constipation, and congenital hyperinsulinemia.
- Company typePrivate
- Founded2008
- HeadquartersSuzhou, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What PegBio does
PegBio Co., Ltd. (派格生物) is a China-based clinical-stage biopharmaceutical company founded in 2008 and publicly listed on the Hong Kong Stock Exchange under ticker hkg:2565. The company is headquartered in Hangzhou, Zhejiang Province (Suite 606, Building 1, Haozhang Mansion, Gongshu District), and is incorporated as a private limited company in China. With 51–100 employees under CEO Michael Xu, PegBio is focused on the in-house discovery and development of innovative therapeutics for chronic metabolic diseases, with its core scientific platform centered on GLP-1 receptor agonist-based therapies. The corporate mission is to bring innovative and effective treatment options to global patients with chronic diseases.
PegBio's product strategy is built around a pipeline of six differentiated drug candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. The lead indications — T2DM and obesity — sit squarely within the GLP-1 receptor agonist class, one of the highest-growth therapeutic categories in metabolic disease. The MASH, OIC, and congenital hyperinsulinemia programs extend the company beyond mainstream GLP-1 applications into liver disease, gastrointestinal side-effect management, and rare metabolic disorders. PegBio cites 'in-house discovery and development,' 'accumulated industry experience,' and 'established R&D capabilities' as the foundation for its differentiated pipeline, and the GLP-1 Receptor Agonist Platform is characterized as the core proprietary technology with a domain specialization differentiator.
As a clinical-stage developer, PegBio has not disclosed commercial product revenue. Its intended go-to-market upon regulatory approval is pharmaceutical distribution through wholesalers, retail pharmacies, and hospital pharmacies, supplemented by potential licensing and royalty arrangements for pipeline candidates. The company is pre-revenue, with capitalization derived from six disclosed private funding rounds between 2011 and 2020 — most notably a $122 million Series E in December 2020 led by Qianhai Fund of Funds, YF Capital, and Yingke Capital — followed by a Hong Kong public listing. No commercial customers, segment-level revenue, or pricing details are disclosed in the available data, consistent with the pre-commercial stage of the business.
PegBio firmographics
Firmographics- Name
- PegBio
- Legal name
- PegBio Co., Ltd.
- Website
- https://pegbio.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- PegBio Co., Ltd. (派格生物) is a China-based, Hong Kong-listed clinical-stage biopharmaceutical company developing GLP-1 receptor agonist-based therapeutics across a six-asset pipeline targeting type 2 diabetes, obesity, MASH, opioid-induced constipation, and congenital hyperinsulinemia.
- Ownership category
- akta.pro rank
PegBio industry classification
Industry- Product category
- Biopharmaceuticals (Metabolic Disease Therapeutics)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)
Keywords
Where PegBio is headquartered
LocationHeadquarters
- HQ city
- Suzhou
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
PegBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: As a clinical-stage biopharmaceutical company, PegBio's primary revenue model is expected to come from product sales of approved therapeutics, combined with potential licensing and royalty arrangements for its drug pipeline candidates targeting metabolic disorders.
Distribution channels1 record
Marketing channels2 records
PegBio product offering
Product offeringCore offering
PegBio is a clinical-stage biopharmaceutical company that discovers and develops innovative therapeutics for chronic metabolic diseases using a proprietary GLP-1 receptor agonist platform. It maintains a diversified pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia, intended for global commercialization through pharmaceutical distribution channels upon regulatory approval.
Product overview
PegBio is a biotechnology company founded in 2008 that focuses on in-house discovery and development of innovative therapies for chronic diseases, with particular emphasis on metabolic disorders. The company has cultivated a diverse pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. The pipeline represents a portfolio of differentiated therapeutics rather than a unified software platform, each addressing specific chronic disease indications.
Differentiator
Problem solved
Functional benefit
Products and services
- Type 2 Diabetes Program A therapeutic candidate targeting type 2 diabetes mellitus (T2DM), part of PegBio's pipeline of six product candidates focused on metabolic disorders, intended for patients requiring effective blood glucose management.
- Obesity Program A therapeutic candidate targeting obesity, one of the six product candidates in PegBio's pipeline addressing chronic metabolic diseases, intended as a next-generation weight loss therapy.
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) Program A therapeutic candidate targeting metabolic dysfunction-associated steatohepatitis (MASH), addressing liver fat accumulation, inflammation, and risk of cirrhosis in patients with this chronic metabolic liver disease.
- Opioid-Induced Constipation (OIC) Program A therapeutic candidate targeting opioid-induced constipation (OIC), addressing gastrointestinal side effects in patients on opioid pain management therapy.
- Congenital Hyperinsulinemia Program A therapeutic candidate targeting congenital hyperinsulinemia, a rare genetic disorder causing excessive insulin production, addressing hypoglycemia and metabolic dysfunction in affected patients.
Quantifiable outcome
- Global GLP-1 receptor agonist market projected to grow from US$51.9 billion (2024) to US$137.4 billion by 2030, representing significant market opportunity for innovative metabolic disorder therapeutics
Companies that use PegBio
Customer profileSegments5 records
Ideal customer profiles2 records
PegBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PegBio partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights6 records
PegBio competitors and assessment
Company assessmentEmerging players
- Zealand Pharma: Danish clinical-stage biotech developing GLP-1/GLP-2 dual agonists including partnered programs with Sanofi. Comparable metabolic peptide focus with platform overlap on GLP-1 mechanism.
Direct peers
- Terns Pharmaceuticals: Clinical-stage biotech developing TERN-601, an oral GLP-1 RA for obesity. Comparable mechanism, indication, and development stage to PegBio's obesity program.
- Eccogene: Chinese clinical-stage biotech developing ECC5004, an oral small-molecule GLP-1 RA for obesity. Directly comparable as a China-based GLP-1-focused biotech with overlapping metabolic disease targets.
- Sciwind Biosciences: Chinese clinical-stage biotech developing ecoglutide, a long-acting GLP-1 receptor agonist for T2DM and obesity. Comparable pipeline focus, geography, and mechanism approach to PegBio.
- Innovent Biologics: Chinese clinical-stage biotech developing mazdutide, a GLP-1/glucagon dual agonist for T2DM and obesity. Directly comparable to PegBio as a Chinese biotech pursuing GLP-1-based metabolic therapeutics with similar indication focus and development stage.
- Structure Therapeutics: Clinical-stage US biotech developing GSBR-1290, an oral GLP-1 RA for obesity and T2DM. Highly comparable mechanism focus and clinical-stage profile to PegBio.
- Kailera Therapeutics: Clinical-stage biotech developing injectable and oral GLP-1 RAs for obesity. Directly comparable mechanism focus and clinical-stage profile to PegBio's lead obesity asset.
Broad incumbents
- Novo Nordisk: Danish pharmaceutical leader with Ozempic, Wegovy, and Rybelsus establishing the GLP-1 standard of care. Major incumbent that defines the competitive landscape PegBio is entering.
- Eli Lilly: US pharmaceutical leader with Mounjaro and Zepbound (tirzepatide) setting efficacy benchmarks in obesity and T2DM. Major incumbent shaping GLP-1 competitive dynamics.
Regional players
- Hanmi Pharmaceutical: Korean pharmaceutical company with efpeglenatide and other GLP-1 programs targeting metabolic diseases. Comparable mechanism focus and clinical-stage pipeline, with regional Asian market presence similar to PegBio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
PegBio social profiles
Digital presencePegBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
PegBio leadership team
Management profileNumber of profiles
Profiles1 record
PegBio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PegBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PegBio
What does PegBio do?
PegBio is a clinical-stage biopharmaceutical company that discovers and develops innovative therapeutics for chronic metabolic diseases using a proprietary GLP-1 receptor agonist platform. It maintains a diversified pipeline of six product candidates targeting type 2 diabetes mellitus (T2DM), obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia, intended for global commercialization through pharmaceutical distribution channels upon regulatory approval.
Is PegBio a public or private company?
PegBio is a private company. It is classified as public and is currently operating.
When was PegBio founded?
PegBio was founded in 2008. It employs 51 to 100 people.
Where is PegBio based?
PegBio is headquartered in Suzhou, China, in the Asia region.
How does PegBio make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are PegBio's main competitors?
Zealand Pharma is listed as an emerging player. Direct peers are Terns Pharmaceuticals, Eccogene, Sciwind Biosciences, Innovent Biologics, Structure Therapeutics and Kailera Therapeutics. Broad incumbents are Novo Nordisk and Eli Lilly. Hanmi Pharmaceutical is listed as a regional player.
Does PegBio have an API?
No public API is recorded for PegBio.
What industry is PegBio in?
PegBio's product category is Biopharmaceuticals (Metabolic Disease Therapeutics). Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.